See today's BioWorld
To read the full story, subscribe or sign in.

Compass plots a course to phase III with $80M B round for psilocybin in resistant depression

April 28, 2020
By Cormac Sheridan
DUBLIN – Compass Pathways Ltd. raised $80 million in a series B round to continue its development of the psychedelic drug psilocybin in treatment-resistant depression.
BioWorld Financings Neurology/psychiatric Private Series B